Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
ID: 355000Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355000

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-239.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)" aimed at advancing research in precision probiotic interventions. This initiative seeks to support innovative mechanistic studies that explore the variability in human responses to probiotics, focusing on factors such as microbiome composition, genetic background, and lifestyle, with the goal of identifying specific subgroups likely to benefit from these therapies. The grant will provide funding of up to $350,000 for a maximum duration of four years, with applications opening in September 2024 and closing on June 2, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-239-Full-Announcement.html
    PAR-24-239.html
    The Department of Health and Human Services is issuing a Notice of Funding Opportunity (NOFO) to support research aimed at advancing precision probiotic interventions. This initiative, led by several National Institutes of Health (NIH) components, seeks to understand the variability in human responses to probiotics, including factors such as microbiome composition, genetic background, and lifestyle. The R33 exploratory grant program is designed for innovative mechanistic studies, requiring preliminary data to showcase the correlation between host biological patterns and probiotic efficacy. Key goals include identifying specific subgroups likely to benefit from probiotics, developing insights into their mechanisms of action, and enhancing diverse perspectives through a mandated Plan for Enhancing Diverse Perspectives (PEDP) in applications. The grants will support a project budget of up to $350,000 for a maximum of four years, and the funding opportunity opens for applications starting in September 2024, closing by June 2027. The research is critical for refining probiotic therapies, with potential applications in various health sectors, including mental health, gastrointestinal conditions, and cancer treatment. Adherence to NIH guidelines and FDA regulations is essential for grant recipients.
    Similar Opportunities
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)." This initiative aims to support innovative mechanistic research that addresses the variability in individual responses to probiotics, with the goal of developing effective interventions tailored to person-specific biological features. The funding mechanism employs a biphasic approach, where the R61 phase focuses on identifying host biological patterns correlated with probiotic effects through observational studies, and the R33 phase rigorously tests causality in animal or human studies, with a total budget not exceeding $350,000 per year for both phases. Interested applicants must submit their proposals by June 2, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCCIH Natural Product Early Phase Clinical Trial Award (R33), aimed at funding early phase clinical trials focused on natural products such as botanicals and dietary supplements. This funding opportunity encourages research that rigorously evaluates the effects of these products on specific biological targets, with a total budget limit of $1,050,000 in direct costs available for up to three years of support. The initiative is particularly relevant for addressing health issues like chronic pain and gastrointestinal disorders, emphasizing the importance of diverse research collaborations and methodologies. Interested applicants must comply with NIH grants policies and submit their proposals by November 13, 2026, while also enhancing research diversity through a Plan for Enhancing Diverse Perspectives (PEDP). For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), invites applications for the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages research that evaluates the pharmacokinetics, safety, and efficacy of these natural products, with a focus on advancing promising interventions backed by prior scientific evidence. The program is designed to foster innovative clinical research that enhances understanding of the beneficial impacts of natural products on health conditions, while ensuring inclusivity through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $350,000 per year, with a project duration of up to six years contingent upon successful milestone completion, and the application deadline is November 13, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer," aimed at supporting basic research into the human microbiome's role in anti-tumor immune responses. Applicants are required to develop innovative projects that explore the interactions between specific microbes or their metabolites and host immune responses, with a focus on identifying mechanisms that may enhance or inhibit tumor formation. This initiative is significant for advancing cancer research and understanding the implications of microbiome interactions in immunology. The funding, administered under the R01 Research Project Grant mechanism, has no budget limit and is open to a diverse range of eligible organizations, with a project duration of up to five years. Interested parties can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by January 7, 2025.
    Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" through the R21 grant mechanism, aimed at advancing research into innate immune memory, known as trained immunity. This initiative seeks to enhance understanding of the mechanisms, biomarkers, and functional implications of trained immunity, particularly in relation to immune system development, vaccine efficacy, and various diseases, while explicitly prohibiting clinical trials. The grant provides a maximum funding amount of $275,000, with applications accepted starting May 16, 2024, and a closing date of January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer," aimed at supporting exploratory research into the human microbiome's role in anti-tumor immunity. This initiative seeks to elucidate the mechanisms by which specific microbes or their metabolites influence immune responses and inflammation related to tumor formation, with a focus on identifying novel molecular targets for cancer prevention strategies. Eligible applicants include a wide range of organizations, such as educational institutions, nonprofits, and tribal governments, with funding available up to $275,000 for two-year projects. Interested parties should submit their applications by January 7, 2025, and can find additional information at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 exploratory research grant titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics." This grant aims to support preclinical and patient-based studies that investigate how incretin mimetics, specifically GLP-1 and GIP-1 receptor agonists, influence cancer risk, particularly in relation to obesity-related cancers such as thyroid and prostate cancers. The funding, which amounts to a maximum of $275,000 over two years, is intended for projects that do not involve clinical trials, with applications opening in January 2024 and a submission deadline of January 7, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" aimed at stimulating innovation in the implementation and sharing of genomic information in clinical care across diverse populations. This initiative encourages applications for small research projects that explore the integration of genomic data into clinical practice, assess barriers to implementation, and develop innovative data analysis techniques, particularly focusing on underrepresented populations in genomic research. The maximum budget for each application is $50,000 over a two-year period, with a total funding expectation of approximately $150,000 for FY 2024. Interested applicants must submit their proposals by February 12, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovative research in the integration of genomic information into clinical care, particularly for populations experiencing health disparities. This initiative encourages proposals that address implementation science, barriers to genomic medicine, and the integration of genomic data with health and social determinants, with a focus on enhancing health equity among underrepresented groups. The grant provides funding up to $250,000, with applications open from November 1, 2023, until the close date of February 11, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.